CD40 and neoplasm: Moreover, a study demonstrates that using a nanofluidic drug-eluting seed (NDES) for sustained, low-dose intratumoral delivery of CD40 monoclonal antibody can alter the TME and reduce tumor size in mouse models of PDAC [478].